Key takeaways
- KPV is H-Lys-Pro-Val-OH, a three-amino-acid peptide. FDA’s 2026 briefing describes it as a fragment of α-MSH, notes that “KPV” is a common name rather than an adopted drug name, and judged neither of the two forms it assessed, the free base and the acetate salt, well characterised.
- Its research is in mouse colitis models and cell studies. In cell work it did not compete with α-MSH for its binding sites, and FDA staff say its molecular targets remain unknown.
- FDA found no human exposure data, no pharmacokinetic study and no toxicity study; we found no published human study or registered trial (18 Nov 2026).
- FDA staff concluded that potential safety risks of KPV in humans are unknown. HHS wrote in October 2026 that this conclusion reflects an absence of information rather than an observed signal, and that KPV’s historical use “is now documented and quantified”.
- KPV is one of four peptides in the vendor mix sold as KLOW; we found no published study of that mix in any species.
01KPV at a glance
The short version, dated 18 November 2026.
| Question | KPV |
|---|---|
| What it is | A three-amino-acid peptide, H-Lys-Pro-Val-OH (lysine–proline–valine). Molecular weight 342.43 g/mol as the free base and 402.5 g/mol as the acetate salt. |
| Origin | FDA’s 2026 briefing describes it as a fragment of α-melanocyte-stimulating hormone (α-MSH), a hormone made in the pituitary gland. “KPV” is a common name, not an adopted drug name. |
| Evidence tier | T3 (animal) and T4 (cell). No human studies found. |
| Human studies | None that we found (PubMed and ClinicalTrials.gov, 18 Nov 2026). FDA found no human exposure data by any route. |
| United States | Not FDA-approved. In FDA’s compounding Category 2 from September 2023 to 22 April 2026. FDA staff recommended against adding it to the 503A bulks list; the advisory committee voted in favour (July 2026). Named in HHS’s draft enforcement-discretion policy (October 2026), which is not binding and not an approval. |
| UK and EU | No result for KPV on the electronic medicines compendium, a UK medicines database (18 Nov 2026). FDA found no KPV product authorised by the European Medicines Agency. |
| Australia | Not named in the Poisons Standard October 2026 (text searched 18 Nov 2026). Not being named is not approval: the TGA says it is unlawful to import, advertise, manufacture and supply unapproved peptide products. |
| WADA | Not named on the 2026 or 2027 Prohibited List; whether class S0 applies is for anti-doping organisations to decide (see below). |
02What is KPV?
KPV is a peptide of three amino acids: lysine (K), proline (P) and valine (V). HHS’s 2026 policy appendix gives its sequence as H-Lys-Pro-Val-OH. FDA’s 2026 briefing describes it as a fragment of α-melanocyte-stimulating hormone (α-MSH), a hormone made in the pituitary gland that, among other roles, drives melanin production through a receptor called MC1.
The name itself is a problem. FDA staff write that “KPV” is a common name, not a United States Adopted Name, and that they have encountered “multiple salts, and derivatives, including different active moieties, sold commercially under the same common name for similarly situated products”. They assessed the free base and the acetate salt separately and judged neither well characterised, partly because they found no published controls for impurities, aggregates or microbial contamination.
KPV is also sold inside mixed vials. Sellers use the name KLOW for a vial that mixes GHK-Cu, BPC-157, TB-500 and KPV, and we found no published study of that mix in any species (PubMed, 18 Nov 2026). More: what is the “KLOW peptide”?
03How has KPV been studied, and in what models?
In mice and in cells. FDA staff found no study that gave KPV to people.
Mice and human cells, 2008 (T3, T4). Researchers at Emory University exposed two human intestinal cell lines and a human T-cell line to inflammatory signals, with and without KPV, and studied two chemically induced forms of colitis in mice. They measured inflammatory signalling inside the cells, the signalling proteins (cytokines) the cells released, and inflammation in the mouse colon, and reported that KPV enters cells through PepT1, a transporter for small peptides. These are mouse and cell results, not evidence of an effect in people.
How it might act (T4). FDA staff summarised cell studies in which KPV did not displace α-MSH from its binding sites on rat brain tissue, mouse melanoma cells or mouse immune cells, and, unlike α-MSH, did not raise cyclic AMP in cells carrying the MC1 receptor. Proposed explanations centre on PepT1 and on NF-κB, a switch for inflammatory genes. FDA staff conclude that its molecular targets “remain unknown”.
What FDA found missing. FDA staff identified no pharmacokinetic study of KPV, which would show how the body absorbs and clears it, and no toxicity study of any kind in either form: single or repeated exposure, genetic toxicity, reproduction or cancer.
Gut research in context: KPV peptide research: what the mouse and cell studies measured.
04What have regulators said about KPV safety?
FDA found no human safety data on KPV. What exists is regulators’ reasoning, and it does not all point the same way.
FDA. FDA staff found no clinical studies and no human exposure data for KPV by any route, and concluded that “potential safety risks associated with the use of KPV in humans are unknown”. They found no clinical studies or human exposure data on immunogenicity, the tendency to provoke an immune response, or on aggregation, and wrote that there is “insufficient data to conclude” that KPV does not present these risks. FDA’s compounding page says the agency “lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans”.
Adverse-event reports. FDA’s search of FAERS, its adverse-event database, through 3 December 2025 retrieved no KPV reports, and its foods and supplements complaint system held no case in which KPV was given. FDA notes that reporting is voluntary, that it does not receive every report, and that pharmacies compounding under section 503A generally do not report adverse events to it. No reports does not mean no reactions.
HHS. HHS’s October 2026 policy appendix says KPV’s “historical use is now documented and quantified, including substantial single-ingredient use”, where FDA had found the extent of use unknown, and that the safety conclusion of FDA’s drug centre “reflects an absence of information rather than an observed signal”.
None of these sources is a study of KPV in people. How to weigh statements like these: side effects, documented vs unknown. If you have had a reaction to any product: how to report it.
05Is KPV an approved medicine? Status by country
United States. No. FDA’s briefing notes that KPV is not a component of an FDA-approved drug and has no USP or NF monograph. HHS records that KPV sat in FDA’s compounding Category 2 from September 2023 to 22 April 2026, that neither the placement nor the removal changed its status under section 503A, and that FDA’s compounding advisory committee voted in favour of listing it after FDA staff recommended against. HHS then named KPV among six peptides in a policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians compounding with them, under conditions that include a patient-specific prescription and a single active ingredient. The Federal Register notice of 30 October 2026 calls the policy a draft that “is not binding”. It is not an approval. Background: the July 2026 committee vote and the HHS policy.
United Kingdom and EU. A search of the electronic medicines compendium (emc), a database of UK licensed-medicine information, returned no results for KPV on 18 November 2026. For the EU, FDA’s briefing found no KPV product authorised by the European Medicines Agency. More: are peptides legal in the UK?
Australia. KPV is not named in the Poisons Standard October 2026, in force from 1 October 2026 (text searched 18 November 2026). The TGA’s media release of 17 August 2026 says it is unlawful to import, advertise, manufacture and supply unapproved peptide products in Australia; it does not name KPV. More: are peptides legal in Australia?
Sport. KPV is not named on WADA’s 2026 Prohibited List or on the 2027 List, in force from 1 January 2027. Class S0 covers any pharmacological substance not addressed elsewhere on the List “and with no current approval by any governmental regulatory health authority for human therapeutic use”, prohibited at all times; the 2027 List adds “peptides” to its examples. Anti-doping organisations decide whether S0 applies. See peptides and anti-doping.
06What we don’t know about KPV
- Any effect of KPV in people. FDA found no human data, and we found no published human study or registered trial (18 Nov 2026).
- How KPV behaves in the human body. FDA identified no pharmacokinetic study.
- Its toxicity. FDA identified no toxicity study of any kind, including for genetic damage, reproduction or cancer.
- What it acts on. FDA staff say its molecular targets remain unknown.
- What a given vial sold as KPV contains, or in which form. FDA staff assessed two forms, the free base and the acetate salt, and judged neither well characterised; only that lot’s lab report shows what the tested sample held: how to read a COA.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.